Literature DB >> 1660200

Membrane fusion activity, oligomerization, and assembly of the rabies virus glycoprotein.

M A Whitt1, L Buonocore, C Prehaud, J K Rose.   

Abstract

The spike glycoprotein (G protein) of rabies virus (CVS strain) expressed in HeLa cells from cloned cDNA mediated membrane fusion after exposure to pHs of 6.1 or below. Chemical crosslinking showed that the rabies G protein, like the vesicular stomatitis virus (VSV) G protein, could be crosslinked to dimers and trimers, indicating that rabies G protein is a trimer. However, unlike the VSV G protein, rabies G protein trimers were not stable to sedimentation in sucrose gradients, even at a mildly acidic pH which stabilizes the VSV G protein trimers. In addition, we report that the expressed rabies virus G protein was functional because it could assemble into VSV particles (tsO45) lacking VSV G protein and rescue infectivity. These VSV (rabies) pseudotypes were neutralized only by an antibody to the rabies G protein. We also examined the properties of a hybrid protein containing the extracellular domain of the rabies virus glycoprotein and the transmembrane and cytoplasmic domains of the VSV G protein. This protein was transported to the cell surface and could be crosslinked to form dimers and trimers, but had little or no detectable membrane fusion activity. The lack of fusion activity was paradoxical because the hybrid protein could rescue VSV infectivity, although the titers were lower than those obtained with the wild-type rabies G protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660200     DOI: 10.1016/0042-6822(91)90539-n

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders.

Authors:  H Badrane; N Tordo
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Evidence that rabies virus forms different kinds of fusion machines with different pH thresholds for fusion.

Authors:  Stéphane Roche; Yves Gaudin
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Rabies virus infects mouse and human lymphocytes and induces apoptosis.

Authors:  M I Thoulouze; M Lafage; J A Montano-Hirose; M Lafon
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Folding of rabies virus glycoprotein: epitope acquisition and interaction with endoplasmic reticulum chaperones.

Authors:  Y Gaudin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 5.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

6.  Biological function of the low-pH, fusion-inactive conformation of rabies virus glycoprotein (G): G is transported in a fusion-inactive state-like conformation.

Authors:  Y Gaudin; C Tuffereau; P Durrer; A Flamand; R W Ruigrok
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America.

Authors:  K Morimoto; M Patel; S Corisdeo; D C Hooper; Z F Fu; C E Rupprecht; H Koprowski; B Dietzschold
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

8.  Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein.

Authors:  Y Gaudin; H Raux; A Flamand; R W Ruigrok
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity.

Authors:  H Badrane; C Bahloul; P Perrin; N Tordo
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

10.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.